See more : Trident Limited (TRIDENT.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Catalyst Pharmaceuticals, Inc. (CPRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Catalyst Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- 1933 Industries Inc. (TGIF.CN) Income Statement Analysis – Financial Results
- Mandarin Hotel Public Company Limited (MANRIN.BK) Income Statement Analysis – Financial Results
- PropTech Investment Corporation II (PTICU) Income Statement Analysis – Financial Results
- LinkCom Manufacturing Co.,LTD. (6821.TWO) Income Statement Analysis – Financial Results
- LXP Industrial Trust (LXP-PC) Income Statement Analysis – Financial Results
Catalyst Pharmaceuticals, Inc. (CPRX)
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 398.20M | 214.20M | 140.83M | 119.07M | 102.31M | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 488.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 84.53M | 34.39M | 21.88M | 17.04M | 14.76M | 19.92M | 45.69K | 43.41K | 34.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 313.67M | 179.81M | 118.95M | 102.03M | 87.55M | -19.42M | -45.69K | -43.41K | -34.47K | 0.00 | 0.00 | 0.00 | 0.00 | 488.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 78.77% | 83.94% | 84.46% | 85.69% | 85.57% | -3,883.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 93.15M | 19.79M | 16.94M | 16.50M | 18.84M | 19.92M | 11.38M | 11.37M | 11.80M | 10.12M | 8.10M | 2.66M | 3.38M | 2.31M | 5.10M | 8.71M | 2.99M | 989.14K | 1.46M | 378.25K | 0.00 | 137.68K |
| General & Administrative | 47.02M | 28.71M | 23.48M | 20.67M | 33.58M | 15.88M | 7.30M | 7.91M | 8.60M | 4.47M | 2.21M | 2.56M | 2.70M | 2.21M | 2.18M | 2.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 86.69M | 29.47M | 26.15M | 23.57M | 3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 133.71M | 58.18M | 49.63M | 44.23M | 36.88M | 15.88M | 7.30M | 7.91M | 8.60M | 4.47M | 2.21M | 2.56M | 2.70M | 2.21M | 2.18M | 2.18M | 2.04M | 1.91M | 359.28K | 164.70K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 2.88M | 282.00K | 586.90K | 1.59M | 1.29M | 454.16K | 321.61K | 100.39K | 76.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -428.62K | 118.27K |
| Operating Expenses | 259.43M | 77.97M | 66.56M | 60.73M | 55.72M | 35.80M | 18.68M | 19.28M | 20.40M | 14.59M | 10.31M | 5.22M | 6.08M | 4.51M | 7.28M | 10.89M | 5.03M | 2.90M | 1.82M | 542.96K | -428.62K | 255.95K |
| Cost & Expenses | 311.39M | 112.37M | 88.45M | 77.77M | 70.48M | 35.80M | 18.68M | 19.28M | 20.40M | 14.59M | 10.31M | 5.22M | 6.08M | 4.51M | 7.28M | 10.89M | 5.03M | 2.90M | 1.82M | 542.96K | -428.62K | 255.95K |
| Interest Income | 0.00 | 0.00 | 282.00K | 587.00K | 1.59M | 1.29M | 454.16K | 321.61K | 100.39K | 76.23K | 47.42K | 14.98K | 10.99K | 17.86K | 33.47K | 329.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.29M | 454.16K | 321.61K | 100.39K | 76.23K | 47.42K | 14.98K | 10.99K | 17.86K | 33.47K | 329.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 32.88M | 1.49M | 484.00K | 885.32K | 297.73K | 37.98K | 45.69K | 43.41K | 34.47K | 26.57K | 22.48K | 10.89K | 42.84K | 25.74K | 30.23K | 32.76K | 15.76K | 4.93K | 1.37K | 366.00 | 0.00 | 0.00 |
| EBITDA | 119.69M | 101.84M | 52.39M | 41.30M | 31.82M | -35.26M | -18.49M | -18.03M | -20.46M | -13.57M | -8.40M | -6.35M | -6.35M | -4.00M | -7.21M | -10.53M | -5.01M | -2.72M | -1.82M | -542.59K | -428.62K | -255.95K |
| EBITDA Ratio | 30.06% | 47.54% | 37.20% | 34.69% | 31.11% | -7,059.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -817.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 86.81M | 101.84M | 52.39M | 41.30M | 31.82M | -35.30M | -18.68M | -19.28M | -20.40M | -14.59M | -10.31M | -5.22M | -6.08M | -4.02M | -7.28M | -10.89M | -5.03M | -2.90M | -1.82M | -542.96K | -428.62K | -255.95K |
| Operating Income Ratio | 21.80% | 47.54% | 37.20% | 34.69% | 31.11% | -7,059.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -823.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.70M | 2.88M | 282.00K | 586.90K | 1.59M | 1.29M | 267.26K | 1.21M | 165.39K | -917.63K | -1.84M | 1.14M | -308.92K | 17.86K | 33.47K | 329.35K | 887.64K | 172.87K | 16.79K | 3.14K | 0.00 | 0.00 |
| Income Before Tax | 94.51M | 104.72M | 52.67M | 41.89M | 33.41M | -34.00M | -18.41M | -18.07M | -20.23M | -15.51M | -12.15M | -4.08M | -6.39M | -4.01M | -7.24M | -10.56M | -4.14M | -2.73M | -1.81M | -539.82K | 0.00 | -255.95K |
| Income Before Tax Ratio | 23.73% | 48.89% | 37.40% | 35.18% | 32.66% | -6,800.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -819.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 23.10M | 21.64M | 13.19M | -33.09M | 1.53M | 2.58M | 141.22K | -929.54K | -99.47K | 993.87K | 1.84M | -1.16M | 308.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 428.62K | 0.00 |
| Net Income | 71.41M | 83.08M | 39.48M | 74.98M | 31.88M | -34.00M | -18.41M | -18.07M | -20.23M | -15.51M | -12.15M | -4.08M | -6.39M | -4.01M | -7.24M | -10.56M | -4.14M | -2.73M | -1.81M | -539.82K | -428.62K | -255.95K |
| Net Income Ratio | 17.93% | 38.79% | 28.03% | 62.97% | 31.16% | -6,800.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -819.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.67 | 0.80 | 0.38 | 0.72 | 0.31 | -0.33 | -0.21 | -0.22 | -0.25 | -0.24 | -0.27 | -0.14 | -0.29 | -0.22 | -0.48 | -0.81 | -0.33 | -0.36 | -0.29 | -0.18 | -0.15 | -0.11 |
| EPS Diluted | 0.63 | 0.75 | 0.37 | 0.71 | 0.30 | -0.33 | -0.21 | -0.22 | -0.25 | -0.24 | -0.27 | -0.14 | -0.29 | -0.22 | -0.48 | -0.81 | -0.33 | -0.36 | -0.29 | -0.18 | -0.15 | -0.11 |
| Weighted Avg Shares Out | 106.28M | 103.37M | 103.38M | 103.51M | 102.94M | 102.63M | 85.80M | 82.88M | 80.86M | 64.14M | 45.45M | 30.03M | 21.73M | 18.58M | 15.07M | 13.01M | 12.53M | 7.69M | 6.20M | 2.92M | 2.92M | 2.36M |
| Weighted Avg Shares Out (Dil) | 113.75M | 111.38M | 107.80M | 106.24M | 106.02M | 102.63M | 85.80M | 82.88M | 80.86M | 64.14M | 45.45M | 30.03M | 21.73M | 18.58M | 15.07M | 13.01M | 12.53M | 7.69M | 6.20M | 2.92M | 2.92M | 2.36M |
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the...
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases today announced that Richard J....
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
Growth stocks have been steadily marching higher since the 2008 financial crisis. Even so, there are still plenty of compelling bargains in the space.
Catalyst's New CEO Has Big Ideas For The Small Biotech
Richard Daly has watched Catalyst Pharmaceuticals transform. Now, as the company's new CEO, he has some metamorphic ideas of his own.
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Michael Kalb - Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeffrey Del Carmen - Chief Commercial Officer Steven...
Top 10% Biotech Stock Catalyst Pharma Doubles Wall Street's Profit Views
Catalyst Pharmaceuticals doubled Wall Street's earnings expectations late Wednesday, and the biotech stock recovered from an earlier slide.
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Source: https://incomestatements.info
Category: Stock Reports